Immuno-Oncology Resource Center
Immuno-Oncology Resource Center
December 12, 2019
2 min read
Save

Kite submits BLA to FDA for CAR T-cell therapy in mantle cell lymphoma

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Biopharma company Kite, a subsidiary of Gilead, has submitted a biologics license application to the FDA for the company’s investigational chimeric antigen receptor T-cell therapy KTE-X19 for the treatment of adults with relapsed or refractory mantle cell lymphoma.

KTE-X19 is an anti-CD19 autologous CAR T-cell therapy that targets the CD19 protein when it is expressed on the surface of cancer cells. Approval of KTE-X19 would make Kite the first manufacturer with more than one FDA-approved CAR T-cell therapy. Axicabtagene ciloleucel (Yescarta; Kite, Gilead) was approved by the FDA in October 2017 for adults with relapsed or refractory large B-cell lymphoma.

“There remains a significant need for new treatments for patients with relapsed/refractory MCL despite recent advances, so this regulatory filing is an especially important milestone for the MCL community,” Ken Takeshita, MD, Kite’s global head of clinical development, said in a press release. “We look forward to working with the FDA to bring KTE-X19 to appropriate patients as quickly as possible and continuing to deliver on the promise of our industry-leading cell therapy development program with a second CAR T therapy.”Kite said it plans to submit a similar approval application to the European Medicines Agency in early 2020; KTE-X19 has already been designated as a breakthrough therapy for relapsed or refractory mantle cell lymphoma in both the United States and the European Union.

The BLA submission was based on phase 2 data from the multicenter ZUMA-2 trial, which were recently presented at the 2019 ASH Annual Meeting and Exposition. The results showed an overall response rate of 93% and a complete response rate of 67%. Grade 3 or grade 4 cytokine release syndrome was experienced by 15% of patients, whereas grade 3 or grade 4 neurotoxicity was reported in 31% of patients. There were no reported cases of grade 5 CRS or neurotoxicity.

Kite had received previous FDA approval for axicabtagene ciloleucel (Yescarta; Kite, Gilead) in October 2017 for adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Kite officials said that KTE-X19 has the same CAR construct as axicabtagene ciloleucel, but that the manufacturing process for KTE-X19 differs in that it includes the enrichment of lymphocytes that is necessary to treat specific B-cell malignancies.

KTE-X19 is currently being tested in clinical trials for additional indications that include adult acute lymphoblastic leukemia (ZUMA-3), pediatric ALL (ZUMA-4) and chronic lymphocytic leukemia (ZUMA-8).